Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
- PMID: 9426741
- DOI: 10.1016/S0090-4295(97)00408-1
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
Abstract
Objectives: Risk factors for prostate cancer (PCa)-related mortality include old age, black race, and residence in northern latitudes. The objectives of this study are to examine the in vitro and in vivo effects of 1,25-dihydroxycholecalciferol (1,25-D3) and less-hypercalcemic analogues on the Dunning rat prostate adenocarcinoma model.
Methods: To evaluate the effect of 1,25-D3 on PCa in vitro, we used the highly metastatic Mat-lylu (MLL) and moderately metastatic R3327-AT-2 (AT-2) Dunning prostate cell lines, and examined effects on growth, clonogenicity, differentiation, and cell cycle. In vivo analysis included examination of the effects of these compounds on tumor growth and metastasis.
Results: Using both the 3-day MTT and 7-day clonogenic assay, 1,25-D3 demonstrated a growth inhibitory effect with a concentration for 50% inhibition (IC50) of approximately 20 microM for both MLL and AT-2. Cell cycle analysis of treated MLL cells (10 microM 1,25-D3 for 48 hours) had 25% more cells in the G0/G1 phase than did control cells. To examine the in vivo effect of 1,25-D3 and the less hypercalcemic vitamin D analogue, Ro25-6760 (or 6760), on MLL PCa growth and metastasis, tumors (5 x 10(5) cells) were implanted subcutaneously into the flank of Copenhagen rats on the same day that treatment was initiated with 1,25-D3 (1 microgram) or 6760 (1 or 5 micrograms); rats received treatment three times a week. After 3 weeks, 1,25-D3 and 6760 (5 micrograms dosing) resulted in an inhibition of tumor volume and a reduction in the number and size of lung metastases.
Conclusions: These preclinical studies demonstrate the profound in vitro, or in vivo, or both antiproliferative and differentiating effects of 1,25-D3 and 6760 on PCa and suggest that these drugs may have potential beneficial effects in the treatment of advanced PCa.
Similar articles
-
Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8. Cancer Epidemiol Biomarkers Prev. 1999. PMID: 10090302
-
Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.Cancer Res. 1994 Jan 1;54(1):169-74. Cancer Res. 1994. PMID: 7903203
-
19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.Cancer Res. 1998 Aug 1;58(15):3370-5. Cancer Res. 1998. PMID: 9699668
-
[Prostaglandins and prostaglandin analogs: experimental studies on their effect of tumor metastasis].Wien Klin Wochenschr. 1995;107(9):261-77. Wien Klin Wochenschr. 1995. PMID: 7778316 Review. German.
-
Vitamin D-related therapies in prostate cancer.Cancer Metastasis Rev. 2002;21(2):147-58. doi: 10.1023/a:1020836226594. Cancer Metastasis Rev. 2002. PMID: 12465754 Review.
Cited by
-
Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model.J Korean Med Sci. 2012 Sep;27(9):1037-43. doi: 10.3346/jkms.2012.27.9.1037. Epub 2012 Aug 22. J Korean Med Sci. 2012. PMID: 22969249 Free PMC article.
-
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.World J Urol. 2005 Feb;23(1):28-32. doi: 10.1007/s00345-004-0476-y. Epub 2005 Jan 25. World J Urol. 2005. PMID: 15668801 Review.
-
Characterization of Vitamin D insensitive prostate cancer cells.J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):712-6. doi: 10.1016/j.jsbmb.2006.12.008. Epub 2007 Feb 5. J Steroid Biochem Mol Biol. 2007. PMID: 17280828 Free PMC article.
-
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.Clin Cancer Res. 2008 Apr 15;14(8):2437-43. doi: 10.1158/1078-0432.CCR-07-4274. Clin Cancer Res. 2008. PMID: 18413835 Free PMC article. Clinical Trial.
-
Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy.Cancers (Basel). 2021 Sep 6;13(17):4481. doi: 10.3390/cancers13174481. Cancers (Basel). 2021. PMID: 34503291 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical